Cantargia AB (publ) (CANTA.ST)
SEK 1.57
(0.9%)
SEK 1.57
(0.9%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -280.02 Million SEK | 22.66% |
| 2022 | -362.07 Million SEK | 1.21% |
| 2021 | -366.5 Million SEK | -111.75% |
| 2020 | -173.08 Million SEK | -56.37% |
| 2019 | -110.69 Million SEK | -21.42% |
| 2018 | -91.16 Million SEK | -51.3% |
| 2017 | -60.25 Million SEK | -34.85% |
| 2016 | -44.68 Million SEK | -159.92% |
| 2015 | -17.19 Million SEK | -105.37% |
| 2014 | -8.37 Million SEK | -5.34% |
| 2013 | -7.94 Million SEK | -129.31% |
| 2012 | -3.46 Million SEK | -2.24% |
| 2011 | -3.38 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -43.29 Million SEK | -17.14% |
| 2024 Q1 | -36.95 Million SEK | 48.14% |
| 2023 Q3 | -76.45 Million SEK | -35.55% |
| 2023 Q1 | -74.27 Million SEK | 18.82% |
| 2023 Q4 | -71.25 Million SEK | 6.8% |
| 2023 Q2 | -56.4 Million SEK | 24.07% |
| 2023 FY | -280.02 Million SEK | 22.66% |
| 2022 Q3 | -62.99 Million SEK | 30.4% |
| 2022 FY | -362.07 Million SEK | 1.21% |
| 2022 Q1 | -113.33 Million SEK | -8.79% |
| 2022 Q4 | -91.49 Million SEK | -45.25% |
| 2022 Q2 | -90.5 Million SEK | 20.14% |
| 2021 Q2 | -85.89 Million SEK | -18.31% |
| 2021 Q1 | -72.6 Million SEK | -28.52% |
| 2021 Q3 | -103.82 Million SEK | -20.88% |
| 2021 Q4 | -104.18 Million SEK | -0.34% |
| 2021 FY | -366.5 Million SEK | -111.75% |
| 2020 FY | -173.08 Million SEK | -56.37% |
| 2020 Q1 | -39.98 Million SEK | -10.23% |
| 2020 Q2 | -37.06 Million SEK | 7.32% |
| 2020 Q3 | -39.55 Million SEK | -6.72% |
| 2020 Q4 | -56.48 Million SEK | -42.82% |
| 2019 Q1 | -23.52 Million SEK | 15.56% |
| 2019 FY | -110.69 Million SEK | -21.42% |
| 2019 Q4 | -36.27 Million SEK | -39.52% |
| 2019 Q3 | -26 Million SEK | -3.95% |
| 2019 Q2 | -25.01 Million SEK | -6.33% |
| 2018 Q3 | -21.45 Million SEK | 23.77% |
| 2018 Q1 | -13.69 Million SEK | 18.08% |
| 2018 Q4 | -27.85 Million SEK | -29.84% |
| 2018 Q2 | -28.14 Million SEK | -105.47% |
| 2018 FY | -91.16 Million SEK | -51.3% |
| 2017 FY | -60.25 Million SEK | -34.85% |
| 2017 Q3 | -11.05 Million SEK | 27.71% |
| 2017 Q2 | -15.29 Million SEK | 10.93% |
| 2017 Q1 | -17.17 Million SEK | -6.21% |
| 2017 Q4 | -16.72 Million SEK | -51.23% |
| 2016 Q2 | -7.92 Million SEK | 2.11% |
| 2016 Q3 | -12.48 Million SEK | -57.53% |
| 2016 Q4 | -16.17 Million SEK | -29.51% |
| 2016 FY | -44.68 Million SEK | -159.92% |
| 2016 Q1 | -8.09 Million SEK | -61.83% |
| 2015 Q4 | -5 Million SEK | -60.0% |
| 2015 FY | -17.19 Million SEK | -105.37% |
| 2015 Q3 | -3.12 Million SEK | 42.44% |
| 2015 Q2 | -5.43 Million SEK | -49.77% |
| 2015 Q1 | -3.62 Million SEK | -42.38% |
| 2014 FY | -8.37 Million SEK | -5.34% |
| 2014 Q1 | -1.86 Million SEK | 28.57% |
| 2014 Q3 | -2.11 Million SEK | -15.02% |
| 2014 Q4 | -2.54 Million SEK | -20.41% |
| 2014 Q2 | -1.83 Million SEK | 1.52% |
| 2013 FY | -7.94 Million SEK | -129.31% |
| 2013 Q4 | -2.61 Million SEK | 0.0% |
| 2012 FY | -3.46 Million SEK | -2.24% |
| 2011 FY | -3.38 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -2082.936% |
| BioArctic AB (publ) | 229.24 Million SEK | 222.15% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -1464.659% |
| CombiGene AB (publ) | -35.66 Million SEK | -685.15% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -84.41% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -1607.692% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1660.955% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | -12.648% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 39.932% |
| Mendus AB (publ) | -101.61 Million SEK | -175.566% |
| LIDDS AB (publ) | -40.2 Million SEK | -596.481% |
| Lipum AB (publ) | -37.17 Million SEK | -653.206% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 2401.15% |
| Simris Alg AB (publ) | -37.3 Million SEK | -650.642% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -563.21% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -1079.707% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 27.86% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -55.859% |
| Ziccum AB (publ) | -21.41 Million SEK | -1207.804% |
| AcouSort AB (publ) | -17.08 Million SEK | -1538.639% |
| Active Biotech AB (publ) | -45.8 Million SEK | -511.413% |
| Alzinova AB (publ) | -16.48 Million SEK | -1599.193% |
| Amniotics AB (publ) | -30.87 Million SEK | -807.117% |
| Camurus AB (publ) | 431.44 Million SEK | 164.905% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -1227.709% |
| Genovis AB (publ.) | 61.5 Million SEK | 555.328% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -147.105% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -655.38% |
| Intervacc AB (publ) | -102.85 Million SEK | -172.262% |
| Kancera AB (publ) | -64.88 Million SEK | -331.548% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 5299.165% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -2208.93% |
| NextCell Pharma AB | -41.95 Million SEK | -567.369% |
| Saniona AB (publ) | -95.81 Million SEK | -192.273% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 9.942% |
| Xintela AB (publ) | -54.08 Million SEK | -417.773% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -63833.105% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -1594.771% |
| Corline Biomedical AB | -1.8 Million SEK | -15379.657% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -57.461% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -392.823% |
| Aptahem AB (publ) | -11.11 Million SEK | -2419.844% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -127.538% |
| Fluicell AB (publ) | -26.55 Million SEK | -954.557% |
| Biovica International AB (publ) | -124.82 Million SEK | -124.339% |
| Abliva AB (publ) | -95.5 Million SEK | -193.194% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 14.339% |
| 2cureX AB (publ) | -32.51 Million SEK | -761.145% |
| I-Tech AB | 20.2 Million SEK | 1486.066% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 66.332% |
| Cyxone AB (publ) | -22.98 Million SEK | -1118.091% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -206.372% |
| Biosergen AB | -27.03 Million SEK | -935.718% |
| Nanologica AB (publ) | -75.15 Million SEK | -272.589% |
| SynAct Pharma AB | -215.81 Million SEK | -29.756% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -535.645% |
| BioInvent International AB (publ) | -330.3 Million SEK | 15.221% |
| Oncopeptides AB (publ) | -249.11 Million SEK | -12.411% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -2720.008% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -156.228% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -2297.902% |